• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • Funds

ArchiMed hits €315m hard-cap for Med II fund

  • Amedeo Goria
  • Amedeo Goria
  • 18 September 2017
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Lower-mid-market private equity house ArchiMed has reached a €315m final close for its second pan-European healthcare-dedicated vehicle, Med II.

The GP hit the €315m hard-cap for its second fund after four months on the road. Launched in April 2017 with a €250m target, the vehicle is more than double the size of its predecessor, which held a final close on €150m in June 2015.

The fund follows the industry's standards in terms of fees, including management fee, hurdle rate and carried interest.

Med II

  • Target:

    €250m

  • Launched:

    Apr 2017

  • Closed on:

    €315m (final close), Sep 2017

  • Focus:

    Healthcare

  • Fund manager:

    ArchiMed

As was the case for Med I, Triago acted as placement agent for Med II. Clifford Chance acted as legal and tax adviser and Paris-based audit firm Mazars Group acted as financial adviser.

Med I is now fully invested and completed its first exit in April 2017, selling HIS via a trade sale for an enterprise value in excess of €25m. The HIS divestment reaped close to 2.5x money and a 400% IRR.

Investors
The GP's maiden fund, Med I, raised €150m of commitments from European LPs, according to a statement, while Med II raised capital from approximately 30 LPs from both the US and Europe.

According to a source close to the situation, 93% of its LPs are institutional and one third of them are based in the US.

European investors included endowments, foundations, funds-of-funds, family offices, banks, insurers and sovereign wealth funds, based mainly in Benelux, France, Germany, Switzerland and the UK.

Investments
ArchiMed targets growth investments as well as leveraged buyouts exclusively across the healthcare sector, including medtech, biopharma, care services and preventive healthcare. The fund invests in European businesses with an equity ticket ranging between €5-50m, and aims to complete about 12 transactions.

ArchiMed's current portfolio companies include Swiss-Italian company Medistream; French firms Polyplus Transfection and Fytexia; London-based Deallus Consulting and RehabWorks; Italian-French company Micromed; and Italian business Primo.

People
ArchiMed – Denis Ribon (chair, managing partner); Vincent Guillaumot, Robin Filmer-Wilson (managing partners); Loïc Kubitza, Christoph Böhmer (operating partners).

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Funds
  • Buyout
  • Healthcare
  • France
  • France

More on Funds

Fund closes in US dollars
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • Funds
  • 05 September 2023
Bettina Curtze of Redalpine
Redalpine expands leadership team amid CHF 1bn-plus fundraise

Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO

  • Venture
  • 31 August 2023
Andris K. Berzins of Change Ventures
Change Ventures aims to hold final close for EUR 20m third fund by mid-2024

Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds

  • Funds
  • 31 August 2023
Fund launches in euros
Iron Wolf Capital targets EUR 70m for second vehicle

Baltic investor anticipates early 2024 launch and will focus on early-stage AI and deeptech startups

  • Funds
  • 30 August 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013